The phase 3 PSMAddition trial demonstrated that the radioligand therapy Lutetium-177 PSMA-617 (Pluvicto) provides a ...

During a live event, Lori Wirth, MD, discussed next steps for treating a patient with progressive, radioactive ...

On October 8, 2025, the US FDA approved the immunotherapy cemiplimab-rwlc (Libtayo) for adjuvant treatment of adult patients ...

Justin Watts, MD, associate professor in the hematology division at Sylvester Comprehensive Cancer Center and part of the ...

The ultimate recommendation is to utilize immune checkpoint blockade in the front-line setting, even for pMMR patients. This ...

Dabrafenib plus trametinib significantly improved progression-free survival and overall response rate in BRAF V600-mutated differentiated thyroid cancer compared to placebo. The study was a global, ...

The triplet therapy of ciforadenant, nivolumab (Opdivo), and ipilimumab (Yervoy) showed acceptable safety but failed to improve efficacy in patients with untreated, advanced clear cell kidney cancer ...

The US FDA has accepted the new drug application (NDA) for XS003, a formulation referencing the tyrosine kinase inhibitor (TKI) nilotinib (Tasigna), for treatment of chronic myeloid leukemia (CML). 1 ...

The trial, also referred to as KEYNOTE-905, met its primary end point of EFS, resulting in a 60% reduction in the risk of tumor recurrence, progression, or death of patients treated with neoadjuvant ...

FDA prioritizes review of enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, showing promising results in reducing recurrence and mortality.

During a live event, Sara Nunnery, MD, MSCI, and participants discussed impressions of recent data from the ASCENT-04 and ASCENT-03 trials.

Pembrolizumab (Keytruda) administered before and after surgery reduced the risk of death by 26% vs placebo in patients with early-stage non–small cell lung cancer (NSCLC), according to 5-year ...